We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
- Authors
CASTERA, L.; CONSTANT, A.; HENRY, C.; CHAMPBENOIT, P.; BERNARD, P.‐H.; DE LEDINGHEN, V.; DEMOTES‐MAINARD, J.; COUZIGOU, P.
- Abstract
Background The psychiatric side effects of interferon, often responsible for dose reduction or treatment discontinuation, represent a major limitation in the treatment of chronic hepatitis C (CHC). Aim To prospectively assess the impact on adherence and sustained virological response (SVR) of the occurrence of psychiatric side effects during peginterferon and ribavirin therapy for CHC. Methods Ninety-eight consecutive treatment-naïve CHC patients receiving a standard course of peginterferon plus ribavirin were systematically screened for psychiatric side effects, using DSM-IV, at baseline and both during and after treatment. Results Psychiatric side effects occurred in 38 patients (39%), mostly within the first 12 weeks (87%), and always consisted of mood disorders. Overall, 68% of patients achieved an SVR (71% of patients with mood disorders and 68% of those without; P = N.S.). Peginterferon and ribavirin dose reductions did not differ between patients with mood disorders and those without (46% vs. 37%, respectively; P = N.S. and 13% vs. 22%, respectively; P = N.S.). Anti-viral therapy had to be discontinued in four patients (nonresponse: two, hyperthyroidism: one, psychiatric event: one). Conclusion Early detection and appropriate management of psychiatric side effects during peginterferon and ribavirin therapy for CHC allow optimizing adherence and virological efficacy.
- Subjects
INTERFERONS; DRUG side effects; HEPATITIS C; RIBAVIRIN; AFFECTIVE disorders
- Publication
Alimentary Pharmacology & Therapeutics, 2006, Vol 24, Issue 8, p1223
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2006.03107.x